In Episode 442 of 'Relentless Health Value,' host Stacey Richter shares an intriguing outtake from a previous episode featuring Andreas Mang, senior managing director at Blackstone, discussing the critical issue of cost management in oncology side effect treatment.

The conversation delves into the inefficiencies and patient harms caused by inadequate side effect management, particularly dehydration due to chemotherapy, and the resulting financial burdens on employers, taxpayers, and patients. 

Stacey explores the importance of a value-based mindset in drug purchasing, integrating oncology care, and the potential financial and health benefits of better side effect management. She highlights various expert opinions and studies supporting these points, encouraging listeners to reconsider their approach to healthcare cost structures and patient care protocols.

If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. 

01:12 Andreas Mang on oncology medication side effect management.

03:12 Mark Lewis, MD’s Tweet.

03:39 Celena Latham’s response.

04:22 How integrative oncology can save money and what it looks like.

04:47 EP157 with Ethan Basch, MD.

06:20 Why PBMs saving money doesn’t necessarily mean savings for employers and payers.

07:36 EP435 with Dan Mendelson.

08:20 EP372 with Cora Opsahl.

08:40 EP331 with Al Lewis.

09:50 Stacey’s second rumination.

10:19 Why having a value mindset when purchasing is a thing.

10:42 Stacey’s third rumination.

12:03 EP370 with Erik Davis and Autumn Yongchu.

13:07 Why FFS does not pay or pay adequately for side effect management.

14:31 Stacey’s final rumination.

17:08 Summarizing Stacey’s four ruminations on this topic.